Investigator Brochure: Contents & Updates

The Investigator’s Brochure (IB) is the sponsor-produced compilation of clinical and nonclinical data on an investigational product that every investigator, site, and reviewing IRB/IEC must have on file before a trial starts and throughout its conduct. ICH E6(R2) Good Clinical Practice, Section 7, sets out both what the document must contain and the sponsor’s ongoing obligation to keep it current. This guide covers the two things a study team actually has to execute against: the required contents checklist, and the update procedure that keeps the IB from going stale mid-trial. For the formal definition and worked examples, see the Investigator’s Brochure (IB) dictionary entry.

IB contents checklist (ICH E6(R2) Section 7)

ICH E6(R2) does not mandate a rigid template, but Section 7 and its structural guidance describe the sections a compliant IB should contain, in roughly this order. Use this table as a completeness check when reviewing a draft IB or a CRO-delivered one.

Section	What it contains	Why it matters to the investigator
Title page & signature/authorization	Product name, sponsor, edition/version number, date, and typically the person(s) responsible for the content	Establishes exactly which version is in force at the site
Confidentiality statement	Sponsor’s confidentiality notice to the investigator/institution	Sets handling expectations for proprietary data
Table of contents	Navigation for the full document	Lets reviewers and IRB/IEC members find the relevant section quickly
Summary	A brief (often ~2-page) overview of the significant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, and clinical information available	Gives a fast risk-benefit orientation before the full detail
Introduction	Chemical/generic name, active ingredients, therapeutic class, and rationale for the proposed trial(s)	Frames why this product is being studied
Physical, chemical & pharmaceutical properties and formulation	Description of the substance(s) and formulation, including known instability or handling precautions	Informs storage, handling, and dispensing procedures at the site
Nonclinical studies	Pharmacology, pharmacokinetics/metabolism, and toxicology data from animal or in vitro studies, with enough methodological detail (species, dose, route) to judge relevance	Basis for dose selection and identifying species-specific findings relevant to human risk
Effects in humans	Pharmacokinetics/metabolism, safety and efficacy findings from prior human studies, and marketing experience if the product is marketed elsewhere	Direct evidence of how the product behaves in people, including known adverse reactions
Summary of data and guidance for the investigator	An integrated discussion of the nonclinical and clinical data, with practical guidance on anticipated adverse reactions, safety monitoring, and dose-related precautions	The section investigators use most directly for day-to-day trial conduct decisions

A marketed product’s approved label or Summary of Product Characteristics can substitute for a full IB only when the product is approved and the trial stays largely within the terms of that labeling (ICH E6(R2) Section 7.1). A trial studying a new indication, population, dose, or route still needs a proper IB, or a supplement covering the new use, regardless of whether the product is marketed elsewhere.

Who is responsible for the IB

Under ICH E6(R2) Section 5 (Sponsor Obligations), the sponsor owns the IB end to end: compiling it, reviewing and updating it, and ensuring the current version reaches investigators, the reviewing IRB/IEC, and regulatory authorities in a timely way. This work is frequently delegated to a contract research organization under a written transfer of duties — see Sponsor vs. CRO for how that delegation typically splits in practice — but the sponsor retains ultimate accountability for IB content and currency. At the site level, the investigator and institution are responsible for making sure the IRB/IEC has the current IB on file, and the current edition is retained in the Investigator Site File (ISF) as an essential document. FDA’s parallel expectations for investigator conduct, including reliance on the current investigational product information, are set out in 21 CFR 312.60.

Annual update procedure

The IB is not a one-time submission. ICH E6(R2) Section 7 imposes two distinct update triggers, and a study team needs a process for both:

Scheduled annual review. The sponsor must review the IB at least once a year and update it if warranted, even in the absence of a specific new finding. In practice this is typically built into a sponsor’s pharmacovigilance and regulatory-affairs calendar as a recurring milestone tied to the product’s development anniversary or IND/CTA anniversary date, not to a fixed calendar date across all products.
Event-driven update. Whenever significant new safety or other relevant information becomes available — for example, a newly confirmed drug-related serious adverse event, a new nonclinical toxicology finding, or a meaningful change in the benefit-risk assessment — the sponsor must produce a revised IB or a formal addendum/safety update promptly, independent of where the annual review cycle stands.

The mechanics of either path are the same:

Revise and version. The updated IB (or addendum) carries an incremented edition/version number and a new date on the title page, so every recipient can confirm they hold the current version.
Distribute. The sponsor (or delegated CRO) sends the revised IB or addendum to all participating investigators and sites, and to the reviewing IRBs/IECs and applicable regulatory authorities.
File. Sites replace the superseded edition in the ISF with the current one and retain a record of the version history.
Reassess. Investigators review the new information against ongoing participants — re-evaluating eligibility, consent, and monitoring where the update materially changes the known risk profile.

Keeping the IB current is not a paperwork formality: whether an adverse event is classified as “unexpected” for expedited safety reporting is judged against what the current IB describes, not against general product knowledge. An IB that missed its annual review, or wasn’t updated after a known safety signal, can distort that classification and is a recurring finding in sponsor and site inspections.

Frequently asked questions

What does “IB” mean in a clinical trial?

In a clinical trial context, “IB” is the Investigator’s Brochure — the sponsor’s compilation of nonclinical and clinical data on an investigational product, supplied to every investigator and the reviewing IRB/IEC under ICH E6(R2) Section 7. It is distinct from the protocol (which describes how the trial is conducted) and from the informed consent form (which is written for participants) — the IB is the risk-benefit reference document for investigators and reviewers.

What has to be in an Investigator’s Brochure?

At minimum: a title page with edition/version and date, a confidentiality statement, a summary, an introduction, physical/chemical/pharmaceutical properties, nonclinical study data, effects in humans, and a summary of data with practical guidance for the investigator. See the contents table above for what each section covers.

How often must the Investigator’s Brochure be updated?

At least annually, as a scheduled review, and additionally whenever significant new safety or other relevant information becomes available — whichever comes first. There is no fixed maximum interval beyond the annual review requirement; a fast-moving safety signal can require an addendum within weeks of the prior edition.

Can an approved drug’s label replace the IB?

Only when the product is already approved and the trial stays largely within the terms of that approved labeling (ICH E6(R2) Section 7.1). Studying a new indication, population, dose, or route still requires a proper IB or a supplement addressing the new use.

Who prepares and maintains the IB — sponsor, CRO, or investigator?

The sponsor is accountable for the IB under Section 5, though preparation and maintenance are commonly delegated to a CRO in writing. Investigators and institutions don’t author the IB, but they are responsible for making sure their IRB/IEC and site files hold the current edition.

How is the IB different from an IMPD?

They serve related but distinct purposes. The IB is the ICH E6(R2)-governed document sponsors give to investigators and IRBs/IECs to support trial conduct decisions. The Investigational Medicinal Product Dossier (IMPD) is the EU clinical-trial-application submission to regulators, built on the ICH Common Technical Document format; EU rules explicitly permit the sponsor to cross-reference the IB and protocol in the IMPD’s nonclinical/clinical sections rather than duplicating that content.

Investigator Brochure: Contents and Updates

Ask about Investigator Brochure: Contents and Updates